US 11,858,876 B2
CCL2 inhibitors
Bruce Kovacs, Irvine, CA (US); Kamron Shahbahrami, Irvine, CA (US); and George Nicola, San Diego, CA (US)
Assigned to LAPKO INC., Las Vegas, NV (US)
Filed by LAPKO INC., Las Vegas, NV (US)
Filed on Sep. 24, 2021, as Appl. No. 17/484,498.
Application 17/484,498 is a division of application No. 16/620,493, granted, now 11,130,729, previously published as PCT/US2018/037061, filed on Jun. 12, 2018.
Claims priority of provisional application 62/518,929, filed on Jun. 13, 2017.
Prior Publication US 2022/0055981 A1, Feb. 24, 2022
Int. Cl. C07D 295/13 (2006.01); C07C 217/22 (2006.01); A61K 45/06 (2006.01)
CPC C07C 217/22 (2013.01) [C07D 295/13 (2013.01); A61K 45/06 (2013.01)] 8 Claims
 
1. A compound according to Formula 1 below:

OG Complex Work Unit Chemistry
wherein
X is 1-3;
Y is 1-3;
R1 is methyl, ethyl, propyl, butyl, or haloalkyl;
R2 and R2′ are independently selected from methyl, propyl, butyl, alkoxy, haloalkyl, and hydrogen or R2 and R2′ may be fused into a heterocyclic ring with 5 or 6 members;
R3 is methyl, ethyl, alkoxy, carboxylic acid, or haloalkyl; and
R4 is hydrogen, hydroxyl or halogen,
or a pharmaceutically acceptable salt, addition compound or pro-drug thereof.